Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy
(2016)
Journal Article
Sykes, D. A., Bradley, M. E., Riddy, D. M., Willard, E., Reilly, J., Miah, A., …Charlton, S. J. (2016). Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy. Molecular Pharmacology, 89(5), 593-605. https://doi.org/10.1124/mol.115.101832
Here we describe the pharmacologic properties of a series of clinically relevant chemoattractant receptor-homologous molecules expressed on T-helper type 2 (CRTh2) receptor antagonists, including fevipiprant (NVP-QAW039 or QAW039), which is currently... Read More about Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy.